Literature DB >> 22297819

Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?

Adham S Bear1, Richard A Morgan, Kenneth Cornetta, Carl H June, Gwendolyn Binder-Scholl, Mark E Dudley, Steven A Feldman, Steven A Rosenberg, Sheila A Shurtleff, Cliona M Rooney, Helen E Heslop, Gianpietro Dotti.   

Abstract

Mesh：

Year:  2012        PMID： 22297819      PMCID： PMC3277217          DOI： 10.1038/mt.2011.288

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

1.  Production of high-titer helper virus-free retroviral vectors by cocultivation of packaging cells with different host ranges.

Authors:  C M Lynch; A D Miller
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry.

Authors:  A D Miller; F Chen
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors.

Authors:  J Chen; L Reeves; K Cornetta
Journal:  Hum Gene Ther       Date:  2001-01-01       Impact factor: 5.695

5.  Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.

Authors:  Bianca Heemskerk; Ke Liu; Mark E Dudley; Laura A Johnson; Andrew Kaiser; Stephanie Downey; Zhili Zheng; Thomas E Shelton; Kant Matsuda; Paul F Robbins; Richard A Morgan; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

6.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus.

Authors:  A D Miller; J V Garcia; N von Suhr; C M Lynch; C Wilson; M V Eiden
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

7.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Authors:  Martin A Pule; Barbara Savoldo; G Doug Myers; Claudia Rossig; Heidi V Russell; Gianpietro Dotti; M Helen Huls; Enli Liu; Adrian P Gee; Zhuyong Mei; Eric Yvon; Heidi L Weiss; Hao Liu; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Nat Med       Date:  2008-11-02       Impact factor: 53.440

Review 8.  Adoptive cell therapy for the treatment of patients with metastatic melanoma.

Authors:  Steven A Rosenberg; Mark E Dudley
Journal:  Curr Opin Immunol       Date:  2009-03-21       Impact factor: 7.486

9.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

10.  Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.

Authors:  R E Donahue; S W Kessler; D Bodine; K McDonagh; C Dunbar; S Goodman; B Agricola; E Byrne; M Raffeld; R Moen
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307
View more
  22 in total

Review 1.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

2.  T lymphocytes are not immune.

Authors:  Gianpietro Dotti
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

Review 3.  Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Authors:  Marcela V Maus; Stephan A Grupp; David L Porter; Carl H June
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

4.  Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Authors:  Katherine T Marcucci; Julie K Jadlowsky; Wei-Ting Hwang; Megan Suhoski-Davis; Vanessa E Gonzalez; Irina Kulikovskaya; Minnal Gupta; Simon F Lacey; Gabriela Plesa; Anne Chew; J Joseph Melenhorst; Bruce L Levine; Carl H June
Journal:  Mol Ther       Date:  2017-10-20       Impact factor: 11.454

5.  Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples.

Authors:  Deborah Lyon; Natasha Lapteva; Adrian P Gee
Journal:  Mol Ther       Date:  2017-12-09       Impact factor: 11.454

6.  Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy.

Authors:  Helen E Heslop; Malcolm K Brenner
Journal:  Mol Ther       Date:  2017-12-20       Impact factor: 11.454

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

9.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

Review 10.  Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.

Authors:  Valentina Hoyos; Barbara Savoldo; Gianpietro Dotti
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.